Cassava Sciences reported $-14090000 in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Abbott USD 2.07B 415M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
Cassava Sciences USD -14090000 15.4M Jun/2025
Eisai JPY 20.74B 21.77B Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
Geron USD -12454000 4.25M Jun/2025
J&J USD 6.94B 6.69B Jun/2025
Merck USD 6.36B 494M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Roche Holding CHF 4.39B 1.04B Dec/2024